Picture of Pharmadrug logo

PHRX Pharmadrug Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+56.64%
3m+51.13%
6m-29.61%
1yr-63.08%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-11.11%
Return on Equity16.76%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Pharmadrug EPS forecast chart

Profile Summary

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    September 30th, 2023
    Incorporated
    September 6th, 2011
    Public Since
    August 16th, 2018
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    104,556,647

    PHRX Share Price Performance

    Upcoming Events for PHRX

    Pharmadrug Inc Annual Shareholders Meeting

    Similar to PHRX

    Picture of 1933 Industries logo

    1933 Industries

    ca flag iconCanadian Securities Exchange

    Picture of 1CM logo

    1CM

    ca flag iconCanadian Securities Exchange

    Picture of Acreage Holdings logo

    Acreage Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Adastra Holdings logo

    Adastra Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Aion Therapeutic logo

    Aion Therapeutic

    ca flag iconCanadian Securities Exchange

    FAQ